These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33086062)

  • 21. Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming.
    Koutsioumpa M; Hatziapostolou M; Polytarchou C; Tolosa EJ; Almada LL; Mahurkar-Joshi S; Williams J; Tirado-Rodriguez AB; Huerta-Yepez S; Karavias D; Kourea H; Poultsides GA; Struhl K; Dawson DW; Donahue TR; Fernández-Zapico ME; Iliopoulos D
    Gut; 2019 Jul; 68(7):1271-1286. PubMed ID: 30337373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormal Peyer patch development and B-cell gut homing drive IgA deficiency in Kabuki syndrome.
    Pilarowski GO; Cazares T; Zhang L; Benjamin JS; Liu K; Jagannathan S; Mousa N; Kasten J; Barski A; Lindsley AW; Bjornsson HT
    J Allergy Clin Immunol; 2020 Mar; 145(3):982-992. PubMed ID: 31816409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of Histone Methyltransferase KMT2D Attenuates Angiogenesis in the Ischemic Heart by Inhibiting the Transcriptional Activation of VEGF-A.
    Meng XM; Liu SB; Deng T; Li DY; You L; Hong H; Feng QP; Zhu BM
    J Cardiovasc Transl Res; 2023 Oct; 16(5):1032-1049. PubMed ID: 36947365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression pattern of Kmt2d in murine craniofacial tissues.
    Dong C; Umar M; Bartoletti G; Gahankari A; Fidelak L; He F
    Gene Expr Patterns; 2019 Dec; 34():119060. PubMed ID: 31228576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The histone methyltransferase KMT2D maintains cellular glucocorticoid responsiveness by shielding the glucocorticoid receptor from degradation.
    Wu CJ; Livak F; Ashwell JD
    J Biol Chem; 2024 Aug; 300(8):107581. PubMed ID: 39025450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
    Guo C; Chen LH; Huang Y; Chang CC; Wang P; Pirozzi CJ; Qin X; Bao X; Greer PK; McLendon RE; Yan H; Keir ST; Bigner DD; He Y
    Oncotarget; 2013 Nov; 4(11):2144-53. PubMed ID: 24240169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
    Morcillo-Garcia S; Noblejas-Lopez MDM; Nieto-Jimenez C; Perez-Peña J; Nuncia-Cantarero M; Győrffy B; Amir E; Pandiella A; Galan-Moya EM; Ocana A
    PLoS One; 2019; 14(4):e0209134. PubMed ID: 30990809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
    Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
    Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The low-complexity domains of the KMT2D protein regulate histone monomethylation transcription to facilitate pancreatic cancer progression.
    Li W; Wu L; Jia H; Lin Z; Zhong R; Li Y; Jiang C; Liu S; Zhou X; Zhang E
    Cell Mol Biol Lett; 2021 Nov; 26(1):45. PubMed ID: 34758724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
    Wang G; Huang Y; Yang F; Tian X; Wang K; Liu L; Fan Y; Li X; Li L; Shi B; Hao Y; Xia C; Nie Q; Xin Y; Shi Z; Ma L; Xu D; Liu C
    Aging (Albany NY); 2020 Feb; 12(3):2030-2048. PubMed ID: 32007952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
    Heward J; Konali L; D'Avola A; Close K; Yeomans A; Philpott M; Dunford J; Rahim T; Al Seraihi AF; Wang J; Korfi K; Araf S; Iqbal S; Bewicke-Copley F; Kumar E; Barisic D; Calaminici M; Clear A; Gribben J; Johnson P; Neve R; Cutillas P; Okosun J; Oppermann U; Melnick A; Packham G; Fitzgibbon J
    Blood; 2021 Aug; 138(5):370-381. PubMed ID: 33786580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
    Lv S; Ji L; Chen B; Liu S; Lei C; Liu X; Qi X; Wang Y; Lai-Han Leung E; Wang H; Zhang L; Yu X; Liu Z; Wei Q; Lu L
    Oncogene; 2018 Mar; 37(10):1354-1368. PubMed ID: 29269867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
    Lv S; Wen H; Shan X; Li J; Wu Y; Yu X; Huang W; Wei Q
    Epigenetics; 2019 Dec; 14(12):1194-1208. PubMed ID: 31232159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation.
    Ang SY; Uebersohn A; Spencer CI; Huang Y; Lee JE; Ge K; Bruneau BG
    Development; 2016 Mar; 143(5):810-21. PubMed ID: 26932671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer.
    Ding B; Yan L; Zhang Y; Wang Z; Zhang Y; Xia D; Ye Z; Xu H
    FEBS Open Bio; 2019 Apr; 9(4):693-706. PubMed ID: 30984543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
    Wang G; Chow RD; Zhu L; Bai Z; Ye L; Zhang F; Renauer PA; Dong MB; Dai X; Zhang X; Du Y; Cheng Y; Niu L; Chu Z; Kim K; Liao C; Clark P; Errami Y; Chen S
    Cancer Discov; 2020 Dec; 10(12):1912-1933. PubMed ID: 32887696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phospho-dependent mechanism involving NCoR and KMT2D controls a permissive chromatin state at Notch target genes.
    Oswald F; Rodriguez P; Giaimo BD; Antonello ZA; Mira L; Mittler G; Thiel VN; Collins KJ; Tabaja N; Cizelsky W; Rothe M; Kühl SJ; Kühl M; Ferrante F; Hein K; Kovall RA; Dominguez M; Borggrefe T
    Nucleic Acids Res; 2016 Jun; 44(10):4703-20. PubMed ID: 26912830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300.
    Kim HJ; Moon SJ; Hong S; Won HH; Kim JH
    Nucleic Acids Res; 2022 Aug; 50(14):7873-7888. PubMed ID: 35801925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KMT2A promotes melanoma cell growth by targeting hTERT signaling pathway.
    Zhang C; Song C; Liu T; Tang R; Chen M; Gao F; Xiao B; Qin G; Shi F; Li W; Li Y; Fu X; Shi D; Xiao X; Kang L; Huang W; Wu X; Tang B; Deng W
    Cell Death Dis; 2017 Jul; 8(7):e2940. PubMed ID: 28726783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Location of PRMT6-Dependent H3R2 Methylation Is Linked to the Transcriptional Outcome of Associated Genes.
    Bouchard C; Sahu P; Meixner M; Nötzold RR; Rust MB; Kremmer E; Feederle R; Hart-Smith G; Finkernagel F; Bartkuhn M; Savai Pullamsetti S; Nist A; Stiewe T; Philipsen S; Bauer UM
    Cell Rep; 2018 Sep; 24(12):3339-3352. PubMed ID: 30232013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.